Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Therapeutic comparison between low-dose sustained-release theophylline dry syrup and capsule in children with mild persistent asthma

유소아 경증 지속성 천식에서 저용량 서방형 테오필린 건조시럽과 캡슐 제형의 치료 효과 비교

  • Lee, Hyun Seung (Department of Pediatrics, College of Medicine The Catholic University of Korea) ;
  • Lee, Hae Kyung (Department of Clinical Pathology, College of Medicine The Catholic University of Korea) ;
  • Kwon, Hi Jeong (Department of Clinical Pathology, College of Medicine The Catholic University of Korea) ;
  • Kim, Jeong Hee (Department of Pediatrics, College of Medicine, Inha University) ;
  • Rha, Yeong Ho (Department of Pediatrics, College of Medicine, Kyunghee University) ;
  • Kim, Jin Tack (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Young Ho (Department of Pediatrics, College of Medicine, Hallym University) ;
  • Lee, Hae Rhan (Department of Pediatrics, College of Medicine, Hallym University) ;
  • Pyun, Bok Yang (Department of Pediatrics, College of Medicine, Soonchunhyang University)
  • 이현승 (가톨릭대학교 의과대학 소아과학교실) ;
  • 이혜경 (가톨릭대학교 의과대학 임상병리학교실) ;
  • 권희정 (가톨릭대학교 의과대학 임상병리학교실) ;
  • 김정희 (인하대학교 의과대학 소아과학교실) ;
  • 나영호 (경희대학교 의과대학 소아과학교실) ;
  • 김진택 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김영호 (한림대학교 의과대학 소아과학교실) ;
  • 이혜란 (한림대학교 의과대학 소아과학교실) ;
  • 편복양 (순천향대학교 의과대학 소아과학교실)
  • Received : 2007.02.05
  • Accepted : 2007.02.15
  • Published : 2007.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Theophylline has recently been reported to have concurrent anti-inflammatory effects at low therapeutic plasma concentrations which are below the doses at which significants, clinically useful bronchodilatation is evident. Sustained-release formulation in capsule and dry syrup forms were developed to reduce its adverse effects and improve its clinical effects. We compared the therapeutic effects of theophylline dry syrup and capsules in children with mild asthma. Methods : Ninety children with mild asthma were randomized to receive either theophylline dry syrup (n=44) or theophylline capsules (n=46); 4 mg per kilogram of body weight, twice a day, for 12 weeks. Baseline and serial measurements of daytime and nighttime asthma symptom score were performed. Compliance scores, drug swallowing scores, and drug usability scores were measured every 4 weeks. Each scoring was rated on a scale of 0-4. Serum theophylline concentration were measured at 4 and at 12 weeks. To examine the anti-inflammatory effect of theophylline on asthma, Serum eosinophilic cationic protein as a marker of airway inflammation caused by eosinophil was measured 12 weeks pre- and post-administration. Results : The daytime and nighttime asthma symptom scores of the two groups after 4 weeks significantly improved over the baseline score. Daytime and nighttime asthma symptom scores in the dry syrup group were statistically lower at all time points except for the nighttime symptom scores at 4 weeks. Compliance scores, drug swallowing scores, and drug usability scores in the dry syrup group were significantly higher at the end time point. Only in the dry syrup group was the serum ECP at the end time point statistically lower than baseline. Conclusion : Low-dose sustained-release theophylline may be safe and effective in bronchial asthma and this effect may be mediated by its anti-inflammatory action mechanisms. Especially, when used in children with asthma, dry syrup formulation is recommended because of its higher compliance than capsule formulation.

목 적 : 테오필린은 천식의 치료제로서 부작용을 개선하기 위하여 서방형 제제가 개발 되었고 캡슐 제형과 더불어 유소아에 대한 임상적용의 편의를 위한 건조시럽 제형이 개발 되어 사용되고 있다. 저자들은 두 가지 테오필린 제형들의 효과를 비교하기 위하여 경증의 천식 환자들에게 테오필린 캡슐 제형과 건조시럽 제형을 저용량으로 투여한 후 제형에 따른 효능을 비교 분석하였다. 방 법 : 2005년 10월 1일부터 2006년 3월 31일까지 가톨릭대학교 의정부성모병원, 경희대학교 경희의료원, 인하대학교 병원, 순천향대학교 병원, 한림대학교 강동성심병원 등의 국내 5개 대학병원 소아 알레르기클리닉에 내원하여 경증 천식으로 진단받은 2-6세 사이 환자 90명을 대상으로 12주 동안 서방형 테오필린을 건조시럽 제형 투여군(n=44)과 캡슐 제형 투여군(n=46)으로 나누어 1일 2회, 4 mg/kg/회의 용량으로 경구 투여하였다. 연구자가 임상 시험 시작(0주)과 매 4주째마다 주간 및 야간 천식 증상 개선도를 평가 하였으며, 매 4주째마다 복약 순응도, 약물 복용감, 그리고 종합적인 평가로서 약제의 유용도를 평가하였다. 이중 약제의 유용도는 환자 보호자에게도 스스로 평가할 수 있게 하였다. 4주와 12주째 혈액내 테오필린 농도와 0주와 12주째 혈액내 ECP농도를 측정하였다. 결 과 : 두 군 모두에서 4주와 12주의 혈액내 테오필린 평균 농도는 $5-10{\mu}g/mL$의 치료 농도를 보였으며 4주째부터 임상시험 시작에 비해 천식 증상의 유의한 호전을 보였다. 두 군간 비교에서는 건조시럽 투여군이 캡슐 투여군보다 주간 천식 증상 점수는 4주째부터 야간 천식 증상 점수는 8주째부터 유의하게 낮은 결과를 보였다. 연구자에 의한 약제의 유용도 평가에 있어서도 건조시럽 투여군이 캡슐 투여군보다 유의하게 높은 결과를 보였으며 평가에 있어서 주관성이 강한 환자 보호자에 의한 평가는 연구자에 의한 평가 보다 4주 먼저 건조시럽 투여군이 캡슐 투여군 보다 유의하게 높게 나타났다. 건조시럽 투여군이 캡슐 투여군 보다 약물 복용감과 복약 순응도가 유의하게 높게 나타났으며 호산구에 의한 기도 염증반응 정도를 반영하는 혈액내 ECP농도는 건조시럽 투여군에서만 12주 동안 테오필린 투약 후가 투약전보다 유의하게 감소하였다. 결 론 : 저용량의 서방형 테오필린은 항염증 작용이 있는 안전하고 유용한 천식 치료제로 생각되며 건조 시럽 제형은 캡슐 제형에 비해 장기간 복약 순응도가 높아서 특히 유소아 천식환자들의 임상적용에 많은 장점이 있는 것으로 사료된다.

Keywords

References

  1. Cho SH, Park HW, Rosenberg DM. The Current status of asthma in Korea. J Korean Med Sci 2006;21:181-7 https://doi.org/10.3346/jkms.2006.21.2.181
  2. Irani AM. The challenge of mild persistent asthma. Ann Allergy Asthma Immunol 2005;94:517-27 https://doi.org/10.1016/S1081-1206(10)61127-1
  3. Barnes PJ. Theophylline : new perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-8 https://doi.org/10.1164/rccm.200210-1142PP
  4. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005;2:334-9
  5. Lim DH. Anti-inflammatory effect of theophylline in asthma management. Pediatr Allergy Respir Dis 2000;10:111-8
  6. National heart lung and blood institute, National institute of health, Global initiative for asthma: Global strategy for asthma management and prevention, NIH Publ No 02-3659, revised 2002;67-79
  7. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci 2002;99:8921-6 https://doi.org/10.1073/pnas.132556899
  8. Choo JH, Nagata M, Sutani A, Kikuchi I. Sakamoto Y. Theophylline attenuates the adhesion of eosinophils to endothelial cells. Int Arch Allergy Immunol 2003;131(1 Suppl): 40S-45S https://doi.org/10.1159/000070480
  9. Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995;8:637-42
  10. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-63 https://doi.org/10.1183/09031936.05.00117504
  11. Miura M, Belvisi MG, Stretton CD, Yacoub MH, Barnes PJ. Role of potassium channels in bronchodilator responses in human airways. Am Rev Respir Dis 1992;146:132-6 https://doi.org/10.1164/ajrccm/146.1.132
  12. Polosa R. Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease. Eur Respir J 2002;20:488-96 https://doi.org/10.1183/09031936.02.01132002
  13. Mascali JJ, Cvietusa P, Negri J, Borish L. Anti-inflammatory effects of theophylline : Modulation of cytokine production. Ann Allergy Asthma Immunol 1996;77:34-8 https://doi.org/10.1016/S1081-1206(10)63476-X
  14. Tomita K, Chikumi H, Tokuyasu H, Yajima H, Hitsuda Y, Matsumoto Y, et al. Functional assay of NF-B translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline. Naunyn Schmidebergs Arch Pharmacol 1999;359:249-55 https://doi.org/10.1007/PL00005349
  15. Ichiyama T, Hasegawa S, Matsubara T, Hayashi T, Furukawa S. Theophylline inhibits NF-B activation and IBa degradation in human pulmonary epithelial cells. Naunyn Schmiedebergs Arch Pharmacol 2001;364:558-61 https://doi.org/10.1007/s00210-001-0494-x
  16. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR. Direct effects of caffeine and theophylline on p110d and other phosphoinositide 3-kinases: differential effects on lipid kinase and protein kinase activities. J Biol Chem 2002;277:37124-30 https://doi.org/10.1074/jbc.M202101200
  17. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis no via phosphodiesterase inhibition. J Clin Invest 1997;100: 1677-84 https://doi.org/10.1172/JCI119692
  18. Chung IY, Nam-Kung EK, Lee NM, Chang HS, Kim DJ, Kim YH, et al. The downregulation of Bcl-2 expression is necessary for theophylline-induced apoptosis of eosinophil. Cell Immunol 2000;203:95-102 https://doi.org/10.1006/cimm.2000.1678
  19. Ohta K, Yamshita N. Apoptosis of eosinophils and lymphocytes in allergic inflammation. J Allergy Clin Immunol 1999;104:14-21 https://doi.org/10.1016/S0091-6749(99)70107-7
  20. Cosio BG, Tsaprouni L, Ito K, Jazrawi E. Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200:689-95 https://doi.org/10.1084/jem.20040416
  21. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953-9 https://doi.org/10.1016/S0092-8674(00)82001-2
  22. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120 https://doi.org/10.1146/annurev.biochem.70.1.81
  23. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, et al. Expression and activity of histone deacetylases (HDACs) in human asthmatic airways. Am J Respir Crit Care Med 2002;166:392-6 https://doi.org/10.1164/rccm.2110060
  24. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004;1:264-8
  25. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1$\beta$-induced histone H4 acetylation on lysine 8 and 12. Mol Cell Biol 2000;20:6891-903 https://doi.org/10.1128/MCB.20.18.6891-6903.2000
  26. Kankaanranta H, Lahdensuo A, Moilanen E, Barnes PJ. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res 2004;5:17 https://doi.org/10.1186/1465-9921-5-17
  27. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate astham. New Engl J Med 1997;337:1412-8 https://doi.org/10.1056/NEJM199711133372002
  28. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997;10:2754-60 https://doi.org/10.1183/09031936.97.10122754
  29. Horiguchi T, Tachikawa S, Kasahara J, Doi M, Shiga M, Miyazaki J, et al. Suppression of airway inflammation by theophylline in adult bronchial asthma. Respiration 1999;66: 124-7 https://doi.org/10.1159/000029353
  30. Grebski E, Wu J, Wüthrich B, Medici TC. Dose eosinophil cationic protein in sputum and blood reflect bronchial inflammation and obstruction in allergic asthmatics? Invest Allergy Clin Immunol 1999;9:82-8
  31. Sorva R, Metso T. Turpeinen M, Backman KJ, Bjrksten F, Haanhtela T. Eosinophil cationic protein in induced sputum as a marker of inflammation in asthmatic children. Pediatr Allergy Immunol 1997;8:45-50 https://doi.org/10.1111/j.1399-3038.1997.tb00142.x
  32. Bacci E, Cianchetti S, Ruocco L, Bartoli ML, Carnevali S, Dente FL, et al. Comparison between eosinophilic markers in induced sputum and blood in asthmatic patients. Clin Exp Allergy 1998;28:1237-43 https://doi.org/10.1046/j.1365-2222.1998.00341.x
  33. Tohda Y, Muraki M, Iwanaga T, Kubo H, Fukuoka M, Nakajima S. The effect of theophylline on blood and sputum eosinophils and ECP in patients with bronchial asthma. Inter J Immunophrarmacol 1998;20:173-81 https://doi.org/10.1016/S0192-0561(98)00026-5
  34. Frigas E, Gleich GJ. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986;77:527-37 https://doi.org/10.1016/0091-6749(86)90341-6